Methyldopahydrazine as an adjunct to L-dopa therapy in parkinsonism.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001794:Blood Pressure; D001921:Brain / Q000378:metabolism; D002648:Child; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use*; D004298:Dopamine / Q000378:metabolism; D005069:Evaluation Studies as Topic; D005260:Female; D005767:Gastrointestinal Diseases / Q000209:etiology; D006321:Heart / Q000187:drug effects; D006801:Humans; D006834:Hydrazines / Q000009:adverse effects / Q000627:therapeutic use*; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D008297:Male; D008750:Methyldopa / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009048:Motor Skills / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism; D010648:Phenylacetates / Q000134:cerebrospinal fluid; D012701:Serotonin / Q000378:metabolism
D006834:Hydrazines; D010648:Phenylacetates; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D008750:Methyldopa; D004295:Dihydroxyphenylalanine; D004298:Dopamine